Skip to main content

IL-17

New FDA Approved for Polymyalgia Rheumatica - Secukinumab

Jack Cush, MD

Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for

Dr. John Cush
@RheumNow
Is It Still Inflammation? A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation? https://t.co/fLGgnBCXS8
Antoni Chan MD (Prof)
@synovialjoints
ACR26 summary, obesity in PsA: 81.8% prevalence of overweight or obesity in a US cohort, lower ACR50 at higher BMI on bimekizumab, and higher ACR50 with ixekizumab plus tirzepatide at 52 weeks. @rheumnow #ACR26 Abstract#2015 Abstract#1305 Abstract#2942
Audrey Gibson
@Gibson_RheumPAC

TOGETHER-PsA by Merola et al may be a practice-changing obesity story. Adding tirzepatide to ixekizumab improved joint outcomes at 52 weeks. Treating inflammation alone may not be enough for some patients with PsA. @rheumnow #ACR2026 #ACRBest Abstract#2942

Audrey Gibson
@Gibson_RheumPAC
Merola et al. (TOGETHER-PsA): In PsA + obesity, adding tirzepatide to ixekizumab improved ACR50 and several disease-activity measures at week 52. Randomized data; open-label design. @rheumnow #ACR2026 Abstract#2942
Audrey Gibson
@Gibson_RheumPAC

Merola et al, TOGETHER-PsA: At 52 weeks, ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone. A 28-point difference! Is addressing obesity becoming essential to optimal PsA care? @rheumnow #ACR2026 #ACRBest Abstract#2942

Janet Pope
@Janetbirdope
NEW #MOA in #SLE TLR7/8 #Afimetoran Drives Interferon T1 TLR7 Changes organ damage TLR8 1 or more background #lupus #Rx mandated #prednisone taper Aim <7.5mg/d #GCs Mean #SLEDAI 8, CLASI 7-8 Mean pred 9.5-10.5 85%HCQ #ACR26 @RheumNow @ACRheum #LB24 https://t.co/EXCnYdc7O3
Janet Pope
@Janetbirdope
#H2H #RCTs in #PsA, #PsO Of #IL17i vs #IL23i /IL12/23i For #PsO IL23i>IL17i #guselkumab >secukinumab #Secukinumab>#ustekinumab for #HAQ DI in PsA #PsA #bimekizumab>#risankizumab depends on what you want as outcome #psoriasis v #psoriatic #arthritis #ACR26 @RheumNow #2804 https://t.co/kOQiC5O68Y

ACR 2026 Day 3 Report

Jack Cush, MD

Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:

Brian Jaros, MD
@Dr_Brian_MD
Secukinumab works regardless of erosive burden in PsA Post-Hoc analysis of FUTURE-5: ACR20 when stratified by baseline erosion score nearly identical in TNF-naive pt ACR20 in TNF-exposed pt numerically higher in those w/ greater erosive burden @rheumnow #ACR26 Abst2285
Brian Jaros, MD
@Dr_Brian_MD
Which patient with ICI joint disease will have persistent disease? Risk factors include: - tenosynovitis on US/MRI - elevated CRP - baseline GC use - age <65 - peripheral inflam arthritis pattern @RheumNow #ACR26 Abst2806
Mrinalini Dey
@DrMiniDey
TOGETHER-PsA (n=271): week 36, 31.7% on ixekizumab + tirzepatide vs 0.8% on ixekizumab alone achieved BOTH ACR50 and >=10% weight loss. Adding tirzepatide to ixe improved PsA disease control as early as WK4 alongside weight loss in overweight or obese pts. #2297 #ACR26 @Rheumnow
×